Articles On Pharmaust (ASX:PAA)

S&P/ASX 200 closes up 1% – its best performance in about a week  All sectors bar IT and Utilities had green days, with Discretionary and Utilities outperforming Resources & Energy Group had a +183% stonker of a day on its you-beaut...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag...

PharmAust could soon move patients in the first cohort of its clinical trial into the use of monepantel to treat Motor Neurone Disease to the third cohort with an increased dosage after confirming its safety. The Trial Safety Committee foun...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Animal research shows mTOR inhibitor drugs could reverse the ageing process Studies also show that they make excellent potential anticancer agents   We profile ASX-listed PharmAust, which has program developing an mTOR inhibitor drug   Ag...

PharmAust continues to progress the first phase of the clinical trial for its lead drug monepantel to treat Motor Neurone Disease with blood samples collected from all patients for interim analysis. The samples from the 12 patients in Cohor...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

An independent study by NYSE-listed Catalent Pharma Solutions shows PharmAust’s (PAA) anti-cancer drug Monepantel (MPL) has long term shelf-live capabilities The Good Manufacturing Practice (GMP) grade stability study tested MPL tablets...

Independent tests have shown PharmAust’s Monepantel (MPL) anti-cancer drug retains long-term shelf life and product stability. The Good Manufacturing Practice (GMP) grade stability study conducted independently by Catalent Pharma Solutions...

The ASX is set to fall on Wednesday after some gloomy earnings forecast on Wall Street Debt ceiling negotiations commence, with a potential US default on the line UBS says last night’s Budget was “stimulatory”, adding pressure on the RBA ...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Research from the Olivia Newton-John Cancer Research Institute on PharmAust’s Monepantel (MPL) anti-cancer drug has been published in the Wiley peer review journal – highlighting that the drug has anti-cancer effects across multiple cancer...

PharmAust’s (PAA) anti-cancer drug Monepantel (MPL) is published in the Wiley peer-review journal after research shows it can treat multiple cancers MPL can stop the growth of different types of cancer cells through apoptosis, where the...

The ASX will open flattish on Tuesday Crude prices rise another 2pc overnight The market awaits the Federal Budget later tonight   The ASX is poised to open modestly higher on Tuesday after a flat session on Wall Street overnight. US trad...

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Investors continue to demonstrate their support for PharmAust with binding commitments received for the raising of $2.5m through an oversubscribed placement. The placement of 30 million shares priced at 8c each, which represents a 20% disco...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms....

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The Phase 2 trial studying PharmAust’s lead drug monepantel (MPL) in dogs with B-cell lymphoma is expected to be completed by mid year. PharmAust (ASX:PAA) says its Phase 2 trial for the treatment of canines with B-cell lymphoma with Monepa...

PharmAust (PAA) continues to report disease response in dogs with cancer treated by the company in a phase II trial of its MPL product Of the 27 dogs fully treated so far, two have shown a partial response — meaning a tumour reduction of...

The ASX is set to open lower on Friday, tracking Wall Street Tesla fell the most since January after Elon Musk’s analysts call The EU has released new regulations on cryptos   The ASX is poised to open lower on Friday, tracking moves in N...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

PharmAust has received additional MPL tablets to ensure it has enough availability for its Phase 1/2 MND trial and future human trials. Clinical-stage biotech PharmAust (ASX:PAA) said pre-release technical specifications of the current Goo...

The ASX is set to rise despite a modest selloff on Wall Street Earnings season begins in the US where major US banks beat expectations Merck and Moderna announced a breakthrough a few hours ago   The ASX is set to open higher on Monday de...

The materials sector took a tumble in early trade, despite plenty of news among the miners. Great Boulder Resources (GBR) has seen a rise in shares after striking further high-grade gold at the recently-discovered eastern lode within its...

PharmAust’s deep pipeline of clinical trials on lead drug Monepantel means that a new CEO with strong knowledge of FDA certifications is needed. Following rapid progress in its clinical trials pipeline, PharmAust (ASX:PAA) announced that it...

PharmAust (PAA) begins an international search for a new CEO as the company progresses to more advanced trial milestones The PAA board says it is looking for someone with a strong knowledge of FDA certification and global licensing agree...

Wall Street fell after report shows US inflation cooled in March US plans to increase EV car sales tenfold by 2032 Expert says go long gold, BTC, and ETH   The ASX is set to open flattish on Thursday after a modest selloff in New York fol...

Biotechnology player PharmAust has completed enrolment of all 12 patients in Cohorts 1 and 2 in its clinical trial of its drug monepantel (MPL) for Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS). The study aims to determine t...

PharmAust (PAA) completes the enrolment of the second cohort of patients in its phase one and two clinical trial testing its monepantel (MPL) drug in MND and ALS The clinical study is assessing the tolerability, safety, pharmacokinetics...

PharmAust (ASX:PAA) says it has completed enrolment of the second cohort of six patients in its Phase 1/2 clinical trial of its lead drug candidate monepantel in Motor Neurone Disease.

Patients from the first cohort treated with PharmAust’s lead drug monepantel under the Phase 1/2 Motor Neurone Disease (MND) clinical trial continue to show no signs of material adverse events. Importantly, the principal investigator has re...

Noxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence extension to manufacture advanced injectable therapies PharmAust patient in motor neurone disease trial elevated to Cohort 2   Biotech company N...

PharmAust (ASX:PAA) has announced a protocol deviation in its trial of Monepantel for treating motor neurone disease.

In PharmAust’s current Phase-2 study in the treatment of B-Cell Lymphoma in Canines with Monepantel (MPL) a 12-year-old Beagle “Louie”, has surpassed 240 days (8 months) because of the treatment, is showing no side effects and his quality o...

PharmAust (PAA) claims a 12-year-old beagle in its clinical trial for the treatment of canine cancer has so far lived for over 240 days with a high quality of life The beagle, Louie, has B-cell lymphoma, which is often fatal within a few...

PharmAust says it’s Phase-2 trial for the treatment of canine B-cell Lymphoma with Monepantel (MPL) is expected to be completed by mid-2023. So far, the company has had some solid results demonstrating anti-cancer activity, with one patient...

PharmAust is looking to expedite the start of Phase-2 clinical trials of its lead drug monepantel for the treatment of Motor Neurone Disease. As part of this push, the company plans to carry out an interim analysis of preliminary biomarkers...

PharmAust (ASX:PAA) says it will undertake an interim analysis of preliminary biomarkers and efficacy markers on completion of dosing of the last patient of Cohort 2 in its motor neurone disease trial of Monepantel.

Protection of PharmAust’s intellectual property has hit a milestone with the impending grant of a key patent relating to the use of Monepantel in conjunction with other drugs to treat cancer. The European Patent Office has issued a Notice o...

PharmAust (PAA) is set to secure a European patent for the use of its Monepantel (MPL) product in combination with other drugs to treat cancer The company has been issued a “notice to grant” from the European Patent Office for pharmaceut...